Skip to main content
. Author manuscript; available in PMC: 2022 Jul 9.
Published in final edited form as: Circ Res. 2021 Apr 30;129(2):221–236. doi: 10.1161/CIRCRESAHA.120.318412

Figure 8: SPHK1 and STAT3 activities are required for S1PR1+ endothelial cell generation in vivo and resolution of lung vascular injury.

Figure 8:

SPHK1 inhibitor, PF-543 (5 mg/kg, i.v) (A, B and E) or STAT3 inhibitor, S3I-201 (5 mg/kg, i.v) (C, D and E) were injected in S1PR1-GFP reporter mice. FACS analysis or lung injury was determined as described in Figure 2. A and C show FACS dot plots of lungs from these mice after with and without inhibitors whereas, B and D depict corresponding quantification (n=7 mice/group). E, lung vascular injury response following treatment with indicated inhibitors as described in Figure 1E (n=5 mice/group). B, D and E show individual data with mean ±SD. Data were analyzed using one-way ANOVA followed by Post hoc Tukey’s multiple comparisons test (See also Online Table II). B, p=0.0003, p=1.77E-10, p=1.99E-11, p=1.99E-11 indicate significance relative to -PF 543 (No SPHK1 inhibitor); D, p=6.38E-14, p=5.78E-14 indicate significance relative to -S3I-201 (No STAT3 inhibitor); E, p=0.0007, p=2.94E-09, p=7.71E-10 indicate significance relative to No LPS; p=0.0002 and p=2.22E-06 indicate significance relative to LPS exposed mice. ns=not significant.